Since the publication of the EMPAREG Outcomes study in 2015 [32] and the LEADERS study [33], SGLT2 inhibitors and GLP1 analogues have been positioned as priority drugs for improving cardiovascular prognosis in patients with diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.